Tag: retinitis pigmentosa
IDT Australia secures $3.2M manufacturing contract for investigational eye therapy
ASX-listed IDT Australia Limited has been awarded a five-year contract valued at $3.2 million for the manufacture of NPI-001 tablets, an investigational treatment for retinitis pigmentosa (RP), a degenerative eye disease that can lead to vision loss.
Featured Article
AMCA Impact Study highlights AI’s role in improving HVAC safety compliance
A new AMCA Impact Study has highlighted the growing challenge of helping HVAC contractors access reliable safety and compliance information quickly, particularly for small and medium-sized businesses operating in Australia's highly regulated construction environment.
